Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ZYME
ZYME
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ZYME News
Zymeworks Announces Q4 and Full Year 2025 Financial Results Release
3d ago
Newsfilter
Zymeworks (ZYME) 2026 Milestones Expected to Drive Long-Term Value with Promising ZW191 Data
Jan 12 2026
NASDAQ.COM
Zymeworks Appoints New Board Member and Executive Leadership Changes
Jan 12 2026
Globenewswire
Zymeworks Appoints New Directors and Executives to Strengthen Leadership Team
Jan 12 2026
Newsfilter
Zymeworks (ZYME) Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera with Up to $440M in Milestone Payments
Jan 12 2026
seekingalpha
Zymeworks Reports Positive Phase 3 Results for Ziihera with Up to $440 Million in Potential Milestones
Jan 11 2026
Globenewswire
Zymeworks Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera with Up to $440M in Milestone Payments
Jan 11 2026
Newsfilter
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Jazz Pharmaceuticals Reports Ziihera Trial Shows Significant Survival Benefits
Jan 07 2026
Benzinga
Zymeworks Reports Significant Survival Improvements in HERIZON Phase 3 Trial for Ziihera
Jan 07 2026
NASDAQ.COM
Zymeworks' Ziihera Shows Positive Phase 3 Results for HER2+ Cancer Treatment
Jan 06 2026
Globenewswire
Zymeworks CEO Kenneth Galbraith Sells 47,528 Shares on December 22, 2025
Dec 22 2025
Yahoo Finance
Zymeworks (ZYME) Price Target Raised by 42.94% to $35.19
Dec 06 2025
NASDAQ.COM
Zymeworks Highlights ZW251 Progress at ASCO GI Conference
Dec 02 2025
Globenewswire
Zymeworks to Showcase ZW251 Clinical Progress at ASCO GI
Dec 02 2025
Newsfilter
Zymeworks to Participate in Upcoming Investor Conferences in Miami
Nov 24 2025
Newsfilter
Show More News
